Uniting TCE Leaders to Optimise Target Selection & Innovate Cell Engager Design to Accelerate Transformative Immunotherapies from Research Towards Clinical Approval
Mitigating on-target, off-tissue toxicity while maintaining efficacy remains a core challenge for the T-cell engager (TCE) field. Yet, with a surge in investment, collaboration and promising clinical data, the space continues to gain momentum. From Cytospire Therapeutics’ oversubscribed £61 million Series A financing to the LabGenius and LG Chem partnership advancing AI-driven cancer antibodies, Europe’s immunotherapy landscape is accelerating rapidly and unlocking new opportunities.
Returning to London in December 2026, the 2nd T-Cell Engager Therapeutics Summit Europe is will bring together industry pioneers and leading experts to showcase the latest advances in target selection technologies, innovative engager designs and strategies for overcoming safety challenges. Across 3 jam-packed days, attendees will gain data-driven insights into accelerating the development of T-cell engager therapeutics across both oncology and autoimmune disease landscapes.
With world-class speakers from GSK, AstraZeneca, Molecular Partners, Immunocore, Enara Bio, Roche, Genmab and more, this is your premier opportunity to stay at the forefront of T-cell engager development, gain insight from industry leaders, and collaborate on solutions to key challenges in safety, efficacy and immunogenicity. Join Europe’s only industry-led forum dedicated to accelerating the development of transformative T-cell engager therapies for patients in need.
I hope to use this meeting to exchange practical insights on next‑generation TCE design, including improving performance in low‑antigen and heterogeneous tumours. I’m particularly interested in how approaches like co‑stimulation, conditional activation, and multi-specific formats translate into real clinical outcomes.
I also value the chance to engage with peers across the pipeline, from discovery through to the clinic. These discussions are important for challenging assumptions, highlighting shared bottlenecks, and identifying where closer collaboration could help move safer, more effective TCE therapies forward.
Duncan Howie, Director, Cell & Immunobiology, Enara Bio
Participating in the 2nd T-Cell Engager Therapeutics Summit Europe is a valuable opportunity to shape the field while learning from peers addressing similar challenges. It enables open exchange on overcoming barriers in serious diseases, refining precision and conditional designs, and building collaborations that accelerate impact. For me, it is about coming together to translate cutting-edge science into meaningful progress for patients.
Marcela Guzmán Ayala, Senior Director & Head, In Vitro Pharmacology, Molecular Partners AG
What makes this meeting especially valuable is its ability to connect scientific innovation with practical development strategy. In oncology, the field has accepted certain risks because of the severity of disease, but that framework does not simply carry over into autoimmune indications. Participating in this meeting is valuable because it creates space for a more mature conversation about what needs to change - in how we assess risk, interpret preclinical data, engage with regulators, and define appropriate dosing strategies. These are the discussions that will determine whether the promise of T cell engagers can be translated safely and credibly to a broader patient population.
Mahnoush Bahjat, Associate Director, Immunology Safety, AstraZeneca
Explore the Full Event Guide
- 21+ expert speakers from pioneering biotech and large pharma, including GSK, Cytospire Therapeutics, AstraZeneca, Enara Bio, T-Cypher Bio, Immunocore, Synolo Therapeutics, Roche and more
- Gain in-depth data-driven insights into achieving selective targeting of tumour-specific antigens, novel engineering approaches and emerging opportunities for TCEs in oncology and autoimmune diseases
- 5 interactive workshops and panel discussions to solve challenges in resistance, T cell exhaustion and on-target/off-tissue tissue to accelerate more efficacious and potent TCEs towards the clinic
Expert Speakers
Sorry, we couldn't find any posts. Please try a different search.
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover the latest breakthroughs shaping TCE development, from novel target selection strategies and innovative engager engineering approaches to translational and clinical insights. Gain exclusive insights from industry leaders during data-driven presentations, interactive workshops and expert panel discussions.
Partner With Us
Showcase your solutions alongside other leading solution providers to a community dedicated to cutting-edge TCE innovation. Position your brand at the heart of the biopharma deals and partnerships defining oncology and autoimmune disease pipelines.
Join TCE Experts
Connect with TCE innovators and engage in the hottest conversations propelling safe and efficacious TCE development. During the dedicated networking sessions, make critical connections, and build meaningful collaborations.